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Background: In recent years, the conﬁdential unit exclusion (CUE) option has been used 
to increase blood safety at blood transfusion centers in several countries. The epidemio-
logic characteristics of diseases and demographic characteristics of patients vary in dif-
ferent countries; therefore, we investigated whether the CUE option is useful in Iran. In 
this study, we determined the prevalences of hepatitis B virus (HBV) and hepatitis C virus 
(HCV) in CUE-positive and CUE-negative units, as well as the eﬃcacy of the CUE option.
Objectives: The aim of this study was to evaluate the eﬃcacy of the CUE option in reduc-
ing the prevalences of HBV and HCV in blood units.
Patients and Methods: All donors were tested for the HCV antibody (anti-HCV) and hepa-
titis B surface antigen (HBsAg). Supplemental tests were performed to conﬁrm the pres-
ence of viruses in the units that tested positive. In total, 2000 units (1000 CUE-positive 
units and 1000 CUE-negative units) were tested using the nucleic acid testing (NAT) 
method. The prevalence of infectious markers was estimated in all demographic sub-
groups.
Results: The prevalences of HBV and HCV markers were higher in donors who opted for 
CUE than in those who did not. The CUE option had low sensitivity (21.5%) and positive 
predictive value (PPV; 20.9%) for the markers. Most of the donors who opted for CUE for 
the ﬁrst time were men with low levels of education.
Conclusions: The CUE option has low sensitivity and PPV, and its eﬀectiveness in reducing 
the transmission of infectious diseases through window-period units is minimal. The 
CUE process can be continued in Iran because Iran is geographically located in a region 
where HBV is endemic; however, higher levels of education are necessary to make this 
process eﬀective. 
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 Implication for health policy/practice/research/medical education:
The implications of the present study could be fruitful for policy makers in the domain of health particularly blood services. 
Moreover, given controversial issues about the eﬃciency of CUE, the ﬁndings of this study would help up decision makers of blood 
services either adopt new plans and programs or make eﬀective modiﬁcations.
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1. Background
Transfusion-transmitted infections (TTIs) are a ma-
jor challenge for all organizations that conduct blood 
transfusions (1). In 2007, the prevalences of hepatitis B 
virus (HBV), hepatitis C virus (HCV), and human imuno-
deﬁciency virus (HIV) in Iranian blood donors were 406 
(per 100,000), 119 (per 100,000), and 3.9 (per 100,000), 
respectively (2). In 2010, the prevalences of HBV and HCV 
in Iranian blood donors decreased to 0.2% and 0.07%, re-
spectively, but the prevalence of HIV in blood donors did 
not change (3). However, state reports suggest that the 
prevalences of HCV and HIV have been increasing in the 
general population. In the USA, the prevalences of HBV, 
HCV, and HIV were 1.5 (per 100,000), 0.3 (per 100,000), in 
2007 (4) and 22.8 (per 100,000), respectively (5). In Tur-
key, the prevalence of HCV (0.07%) was similar to that in 
Iran, but the incidences of HBV and HIV were 1.76% and 
0.008%, respectively, in 2010 (6). The prevalences of HBV 
and HCV were higher in blood donors in Pakistan than in 
Iran. The incidences of HBV and HCV in Pakistan were 2.4% 
and 3.6%, respectively (7). Iran is located between Turkey 
and Pakistan, and the prevalences of HBV, HCV, and HIV 
were lower in the blood donors in Iran than in the blood 
donors in these neighboring countries. Iranian Blood 
Transfusion Organization (IBTO) was successful in de-
creasing post-transfusion infections in multitransfused 
patients. HCV is the most prevalent TTI in these patients.
(1) The seroprevalence of HCV was 2–32% in thalassemia 
patients in Iran (8); however, after the implementation 
of the donor screening tests for HCV, the seroprevalence 
in these patients was found to be 2.5% (9). 
The prevalence of HCV was higher in hemodialysis and 
hemophilia patients than in patients with other TTIs. The 
seropositivities for HCV in hemodialysis and hemophilia 
patients were 21% and 42.5%, respectively.(1) In some re-
gions, the seropositivity for this virus was very high. In 
Gilan, the prevalence of HCV antibody (anti-HCV) was 
55.9% in hemodialysis patients in 2002, but it decreased 
to 24.8% in 2003 (1). Successful donor selection and safety 
programs at the IBTO may have caused this reduction (1). 
The Food and Drug Administration (FDA) recommended 
using the conﬁdential unit exclusion (CUE) process for 
reducing TTI risk in donors who were in the window pe-
riod (10). One of the goals of the CUE process is the exclu-
sion of blood units that may be positive for one of the 
transmissible diseases (11). The CUE process was initiated 
in 1986.(10, 12) At that time, no laboratory method for de-
tecting HIV was present; therefore, excluding HIV-infect-
ed blood was the main goal of the CUE process. Several 
studies have been conducted on the eﬃcacy of the CUE 
process in blood donors; in these studies, the sensitivity 
of CUE in detecting HIV antibody (anti-HIV) varied from 
3% to 47%. The main purpose of CUE is determining high-
risk donors who deny their involvement in high-risk ac-
tivities when ﬁlling the screening questionnaire before 
donation (12). Diﬀerences in the reports about the sen-
sitivity of CUE may be because of the educational status 
of donors and because this process is relatively new in 
many countries.
In 1994, Korelitz et al. performed a study on the eﬃcacy 
of CUE and found that the number of infectious markers 
such as hepatitis B surface antigen (HBsAg), anti-HCV, an-
ti-HIV, and syphilis was 8–41 times higher in CUE-positive 
units than in CUE-negative units. In their study, the posi-
tive predictive value (PPV) and sensitivity of CUE were 
3.5% and 2.3%, respectively (13). In addition, they found 
that women used the CUE option more often than men 
did, and that many of the CUE-positive units had been 
collected from educated ﬁrst-time donors (13). A study 
conducted by Zou et al. in the USA showed that the CUE 
option has low sensitivity (3.7%), and because of this low 
sensitivity, 7000 blood units gad been discarded in the 
USA in 2001 (12). Petersen et al. have shown that donors 
who used the CUE option were more likely to test positive 
for anti-HIV; however, because the units are infrequently 
excluded, the CUE process has minimal impact on blood 
safety (14). In 1995, Brennan et al. reported that CUE is a 
useful method for routine donor selection and decreas-
ing the incidence of TTIs (15). O’Brien et al. have evaluated 
the eﬃcacy of the CUE process by using the nucleic acid 
testing (NAT) method and have shown that the CUE pro-
cess is not a useful safeguard layer (16).
Iran has been using the CUE process since 2003 (17). The 
CUE process was designed for excluding HIV-infected 
blood, and the HIV window period has decreased after 
the use of this process;(12) however, HIV was not selected 
as a criterion in this study because its prevalence among 
blood donors in Iran was 0.005% in 2005 (1). Because 
of this low prevalence of HIV, more blood units were 
required for this study. However, this study was a pilot 
study, and it was not possible to collect many blood units 
because there was no automated system for performing 
extraction and polymerase chain reaction (PCR) tests. In 
this study, we selected the prevalences of HBV and HCV 
for determining the eﬃcacy of the CUE process. HBV was 
chosen because Iran is located in a region where HBV is 
endemic (18); HCV was selected because its prevalence 
has risen from 0.12% (2) in 2007 to 0.5% (11) in 2009. More-
over, molecular methods are available for detecting HCV, 
thereby decreasing its window period. The evaluation of 
the eﬃcacy of CUE is necessary for continuing this pro-
cess. In this study, NAT (a molecular method) was used 
for detecting donors in the window period. This study 
was performed because PCR is not used as a screening 
test in Iran, and the CUE option, which is used in Iran, has 
not been recommended by the FDA since 1992 (19) .
2. Objectives
Some studies have reported that the NAT systems, 
which are used presently, may not be sensitive enough 
to detect all HBV-positive donors (20, 21) . The objective of 
this study was to compare the eﬃcacy of the CUE option 
to that of the NAT method in detecting window-period 
infections. In addition, the correlation between the prev-909 Eﬃcacy of CUE Option in Blood Donors Farhadi E et al.
Hepat Mon. 2011;11(11):907-912
alences of infectious markers and demographic charac-
teristics was determined.
3. Patients and Methods
This study for evaluating of the eﬃcacy of the CUE op-
tion among blood donors at the Tehran transfusion cen-
ter began in 2008. In total, 353612 units of blood were 
donated in a year. We investigated the cause of HBV and 
HCV infections in blood donors. In addition, we analyzed 
demographic characteristics such as age, gender, and 
donation history. All donors were given an information 
sheet and were interviewed about the risk factors by a 
physician; they were then given some bar-coded stickers. 
After studying the information sheet, the donors used 
one of the bar-coded stickers that indicated whether 
they wanted their blood to be excluded. All units were 
tested for the necessary serologic markers at the Tehran 
transfusion center. HBsAg was detected using Enzygnost 
HBsAg 5.0 (Dade Behring), and anti-HCV was detected by 
ORTHO® HCV Version 3.0 ELISA Test System. Conﬁrma-
tory tests for HBV were performed using neutralization 
tests (HBsAg conﬁrmatory assay, Dade Behring), and 
anti-HCV was conﬁrmed using the Recombinant Immu-
noblot 3.0 Assay (INNO-LIA™ HCV Score). We randomly 
collected 1000 CUE-positive blood units and 1000 CUE-
negative blood units and tested them by using the NAT 
method for detecting HBV DNA and HCV RNA; then  all re-
sults of HBV DNA, HCV RNA and other demographic data 
for each sample were surveyed. PCR was performed using 
in-house kits authenticated by the Viral Quality Control 
(VQC) laboratory and National Serology Reference Labo-
ratory (NRL). The CUE forms used in Iran were analyzed 
and compared to the forms used in Germany.(22) 
3.1. Statistical Analysis 
The donors’ database containing their demographic 
characteristics, serologic markers, PCR results, and CUE 
option were analyzed using Statistical Package for the So-
cial Sciences (SPSS) version 16. Chi-square test was used 
for comparing the data. A probability less than 0.05 (P 
< 0.05) and a 95% conﬁdence interval (CI) of odds ratio 
OR less than 1 was considered signiﬁcant. Sensitivity was 
deﬁned as the proportion of CUE-positive donors among 
the donors identiﬁed as having an infection. The PPV was 
deﬁned as the proportion of samples that tested positive 
for infection among the CUE-positive samples.
4. Results
In total, 353612 blood units were obtained from volun-
teers at the Tehran transfusion center between March 
2008 and February 2009. The CUE option was used by 
2072 (0.6%) donors. Variations in CUE according to demo-
graphic characteristics are shown in Table 1. More male 
donors than female donors used the CUE option (OR, 
2.3; 95% CI, 1.797–2.942; P < 0.0001). Among the donors, 
269541 (76.2%) were married; married donors were 0.53 
times less likely than unmarried donors to use the CUE 
process (OR. 0.538; 95% CI, 0.482–0.601; P < 0.0001). Table 
1 shows that fewer donors with higher levels of educa-
tion than those with an under Diploma degree and more 
younger donors than older donors used the CUE option 
(OR, 0.55; 95% CI, 0.486–0.638; P < 0.0001). Fewer repeat 
donors than ﬁrst-time donors used the CUE option (OR, 
0.69; 95% CI, 0.623–0.783; P < 0.0001). Moreover, the fre-
quency of the use of the CUE process by the lapsed do-
nors was 1.5 times less than that of ﬁrst-time donors (OR, 
1.546; 95% CI, 1.353–1.766; P < 0.0001).
Donations, No. P value Adjusted Odds Ratio 95% CI
Gender
Female
Male
331253
22359 0.000
1.0
2.300 1.797–2.942
Age, y
< 28
28–38
> 38
111113
109679
132820
0.000
0.000
1.0
0.557
0.673
0.486–0.638
0.594–0.763
Education
Under diploma
Diploma
Higher than diploma
88231
155516
109865
0.002
0.002
1.0
0.821
0.849
0.726–0.928
0.766–0.940
Donation history
First time
Repeat
Lapsed
142367
132288
78957
0.000
0.000
1.0
0.698
1.546
0.623–0.783
1.353–1.766
Marital status
Unmarried
Married
269541
84071 0.000
1.0
0.538 0.482–0.601
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4.1. Prevalence Rates of Infectious Disease Markers 
The Tehran transfusion center had 353612 voluntary 
donations from March 2008 to February 2009. Of these 
donors, 2072 used the CUE option. Table 2 shows the prev-
alences of HBV and HCV. The prevalences of HBV and HCV 
were signiﬁcantly higher in donors who used the CUE op-
tion (P < 0.05) than in those who did not. However, the 
CUE option had low sensitivity for detecting infection. 
The highest sensitivity for HCV infection was 5.5%. Fur-
thermore, the CUE option has low PPV; the highest PPV 
for HBV infection was 1.5%. Donors who used the CUE op-
tion were more likely than those who did not to develop 
an HBV (OR, 4.63; 95% CI, 3.25–6.60; P < 0.0001) or HCV 
(OR, 10.13; 95% CI, 6.57–15.60; P < 0.0001) infection. De-
mographic subgroups of seropositive donors who used 
the CUE option are shown in Table 3. All donors who used 
the CUE option were classiﬁed according to their demo-
graphic characteristics. The sensitivity of CUE was 21.5%. 
Among the donors whose samples tested positive for 
infection, several subgroups, including females, elderly, 
and married and lapsed donors, were found to be less 
likely to use the CUE option. The higher the educational 
level of the donors, the less likely the positive donors 
were to use the CUE option. The use of the CUE option by 
infected donors decreased with increase in educational 
levels.
5. Discussion 
The CUE process was recommended by the FDA in 1986 
(10, 12). The main goal of the CUE process is detecting 
donors who are infected but are in the window period. 
This process was especially designed for detecting high-
risk donors who denied their involvement in high-risk 
activities during the predonation interview (2). This 
process gives an opportunity to the high-risk donors to 
conﬁdentially exclude their blood (1). In this study, we 
calculated the PPV, which is based on the number of se-
ropositive donors who understate their condition and 
use the CUE option correctly. Previous studies that have 
estimated the sensitivity of CUE have shown that it var-
ies widely between 3% and 47% (23, 24). Diﬀerent sensi-
tivities of CUE were determined at each of the 3 centers 
where a single study was performed, and the sensitivi-
ties were 3%, 4%, and 37%. In this study, the sensitivity was 
estimated to be 21.5% and PPV to be 20.9. Although the 
Positive Units, No. Sensitivity, % 95% CI
Gender
Male
Female
83
2
4.31
2.25
0.0349–0.0531
0.0062–0.0783
Age, y
< 28
28–38
>38
32
29
24
6.43
4.55
2.73
0.0459–0.0893
0.0318–0.0645
0.0184–0.0403
Marital status
Married
Unmarried
55
30
3.47
6.98
0.0267–0.0449
0.0493–0.0978
Education
Under diploma
Diploma
Higher than diploma
37
31
17
3.73
4.18
6.14
0.0272–0.0509
0.0294–0.0584
0.0387–0.0961
Donation history
First time
Repeat
Lapsed
70
7
8
4.48
3.33
3.31
0.0356–0.0562
0.0162–0.0672
0.0168–0.0639
 
Table 3. Demographic Subgroups of Seropositive Donors That Used CUE and the Sensitivity of CUE in These Subgroups
ID Marker Number of Donations Number of Positive P value OR a 95% CI Sensitivity PPV
HBsAg 0.000 4.63 3.25–6.60 0.0263 0.0154
No
Yes
351540
2072
1185
32
Anti-HCV 0.000 10.13 6.57–15.60 0.0558 0.0106
No
Yes
351540
2072
372
22
 
Table 2. The Prevalence of HBV and HCV and the Use of CUE Determined Using Serologic Tests
a Abbreviation: OR, odd ratio911 Eﬃcacy of CUE Option in Blood Donors Farhadi E et al.
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ID Marker Number of Donations Positive Findings, No. P value OR a 95% CI Sensitivity PPV
HBV-NAT 0.0583 6.03 0.728–277.6 0.08571 0.006
No
Yes
1000
1000
0
6
HCV-NAT 0.3168 3 0.240–157.9 0.75 0.003
No
Yes
1000
1000
0
4
 
Table 4. The Prevalences of HBV and HCV and the Use of CUE in the NAT Method in 2000 Units of Blood
a Abbreviation: OR, odd ratio
sensitivity and PPV reported in this study are higher than 
those reported in the study by Zou et al. and Korelitz et 
al., the estimated sensitivity and PPV in this study are low 
for detecting window-period infections. Our data has 
shown that many donors who used the CUE option had 
positive test results; however, the diﬀerences between 
the test results of the CUE-positive and CUE-negative do-
nors were not signiﬁcant. Our ﬁndings were conﬁrmed 
in a study by Omid Khoda et al. They showed that more 
CUE-positive donors than CUE-negative donors had posi-
tive test results of infection (25) . Kean et al. have proved 
that the low sensitivity and PPV of the CUE option could 
be attributed to errors in selecting the CUE option by 
the donors. They reported that most of the donors that 
opted for CUE had said “I wasn’t paying attention” (26). 
Another reason might be the donors’ education, which 
may not have been high enough. Yet another reason may 
be related to the CUE form. According to Sumnig’s study, 
the CUE forms need certain characteristics such as us-
ing pictures instead of text and a colored note instead of 
black note. The CUE form has not yet been evaluated in 
Iran; however, we believe that the evaluation of this form 
may be eﬀective for increasing the sensitivity and PPV 
of the CUE option (22) . Out of the 353612 donors in this 
study, 2072 (0.6%) used the CUE, and among these 2072 
donors, about 21% tested positive for infection; therefore, 
we believe that the donors do not understand the usage 
of the CUE option. Table 1 shows that more donors with 
low levels of education than those with high levels of 
education used the CUE option. More ﬁrst-time donors 
than repeat donors used the CUE option (OR, 0.698; 95% 
CI, 0.623–0.783; P < 0.0001). This ﬁnding conﬁrms our hy-
pothesis because repeat donors are more familiar with 
blood transfusion. In this study, more male donors than 
female donors used the CUE. Women in Iran are reluc-
tant to donate blood because they are afraid of becom-
ing anemic and contacting infections (27). In this study, 
2000 blood units (1000 CUE-positive units and 1000 CUE-
negative units) were tested for HBV DNA and HCV DNA by 
using the NAT method. There were several infected units 
in both the groups, all of which were seropositive for ei-
ther HBV or HCV; consequently, the NAT method was not 
able to detect the blood units that were in the window 
period. The ﬁndings of the NAT method are shown in 
Table 4. The NAT method decreases the window period; 
however, this method does not eliminate the window 
period. Therefore, such tests cannot eliminate the risk of 
transmissible diseases. The number of blood units tested 
using the NAT method was less, and these tests need to 
be repeated with a large number of units. PCR was per-
formed by using in-house kits, none of which was auto-
mated. Furthermore, genome extraction was performed 
manually; therefore, we were unable to test more blood 
units by using the NAT method. Moreover, the NAT meth-
od cannot signiﬁcantly change its window period. Anal-
ysis of the obtained data, suggests that the CUE option 
can be used as an extra safeguard, particularly in Iran 
because it is located in a region where HBV is endemic. In 
conclusion, higher education among the people of Iran 
is necessary for continuation of the CUE process. The for-
mat of the CUE forms may be the cause of its low eﬃcacy; 
thus, a survey on Iran’s CUE forms is necessary, and fur-
ther studies need to be performed for the evaluation of 
the CUE option.
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